Overview
A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765
Status:
Terminated
Terminated
Trial end date:
2011-01-01
2011-01-01
Target enrollment:
0
0
Participant gender:
Male
Male
Summary
This study will provide data to support preclinical to clinical translation by aligning preclinical and clinical efficacy assay with dose dependent changes in EEG.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
AstraZenecaTreatments:
Ketamine
Criteria
Inclusion Criteria:- BMI 18-30 Non-smoker for at least 4 weeks
Exclusion Criteria:
- Any clinically relevant acute or chronic disease
- History of substance abuse Hypersensitivity to ketamine